P-TAU 231

Threonine 231 is one of the phosphorylation sites of human tau (phospho-Tau 231, p-Tau 231). Tau is a microtubule-stabilizing protein primarily localized in neurons of the central nervous system but also expressed at low levels in astrocytes and oligodendrocytes. Tau consists of six isoforms in the human brain with molecular weights of 48 KDa to 67 KDa, depending on isoform. Tau elevation is observed in the cerebrospinal fluid (CSF) of patients with neurodegenerative disease and severe head injuries, suggesting its extracellular release during neuronal damage and a role as a biomarker with specificity for brain injury. In Alzheimer’s disease and related neurodegenerative diseases, including chronic traumatic encephalopathy, tau is abnormally phosphorylated and aggregated into bundles of filaments. Phosphorylated tau has believed to be a more relevant biomarker for Alzheimer’s disease. Tau phosphorylated at threonine 231 has been shown to differentiate Alzheimer’s disease from healthy controls.

p-Tau 231 in Neuropathology

p-Tau 231 is one of the earliest tau epitopes to become phosphorylated in Alzheimer’s disease. It has been shown to be present in the brains of Alzheimer’s disease patients even before the onset of symptoms. This suggests that p-Tau 231 may be a valuable biomarker for the early detection of Alzheimer’s disease.

Applications and Intended Use

The p-Tau 231 assay is a digital immunoassay for the quantitative determination of p-Tau 231 in CSF (Advantage and Advantage PLUS) and plasma (Advantage PLUS).

Compatible Instruments

Advantage PLUS: HD-X
Advantage: HD-1/HD-X/SR-X

Kit Contents

The assay kit includes all necessary reagents and controls to perform 96 tests, making it easy to use and compatible with various sample types.